The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been...